DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Inhibition of Histone Deacetylases (HDACs) and mTOR Signaling: Novel Strategies Toward the Treatment of Prostate Cancer
Annual summary rept. 1 Apr 2010-31 Mar 2011
HEALTH RESEARCH INC BUFFALO NY
Pagination or Media Count:
During the past year I have setup a transplant androgen sensitive and castrate resistant prostate tumor mouse model for pre-clinical evaluation of novel targeted therapies. Further, this tumor is derived from a transgenic mouse of prostate cancer and all studies are performed in immune-competent animals. We have currently submitted 2 manuscripts, the first describing the creation of the transplant tumor model, and the second describing the increased therapeutic efficacy of HDACmTOR inhibitor combination for the treatment of advanced and castrate resistant prostate cancer. We also describe that increased inhibition of androgen receptor and HIF-1 alpha signaling as a major reason for greater therapeutic efficacy by combination therapy. Lastly, this manuscript demonstrates that microRNA may provide novel biomarkers for indication of therapy response. This work is inline with a current clinical trial under recruitment to treat patients with HDACmTOR inhibitor combination who have castrate resistant prostate cancer.
APPROVED FOR PUBLIC RELEASE